Hexyl aminolevulinate

Drug Profile

Hexyl aminolevulinate

Alternative Names: 5-ALA hexylester; 5-ALA hexylesther; aminolevulinic acid hexyl ester; Cevira; Cysview; HAL-PDT; hexaminolevulinate; Hexvix; Hexvix PDT; hexyl 5-aminolevulinate; P 1206

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PhotoCure
  • Developer Photocure
  • Class Amino acids; Antineoplastics; Esters; Levulinic acids; Oxidants; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cervical intraepithelial neoplasia

Highest Development Phases

  • Marketed Bladder cancer
  • Phase II Cervical intraepithelial neoplasia
  • Discontinued Colorectal cancer

Most Recent Events

  • 23 Aug 2017 Photocure anticipates the approval of sNDA in the US for use of BLC™ with Cysview® using KARL STORZ D-Light C PDD Flexible Videoscope System for the diagnosis of Bladder cancer in 2018
  • 16 Aug 2017 Photocure submits sNDA to US FDA to seek approval for use of BLC™ with Cysview® using KARL STORZ D-Light C PDD Flexible Videoscope System, for the diagnosis of Bladder cancer, to expand the indication to include detection of carcinoma in situ and to allow for repeated use
  • 14 May 2017 Efficacy data from a phase III trial in Bladder cancer presented at American Urological Association Annual Meeting (AUA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top